10.01.2019 • NewsDede WillamsRegeneronSanofi

Sanofi Pays to Exit Regeneron Pact

Sanofi Pays to Exit Regeneron Pact
Sanofi Pays to Exit Regeneron Pact

France’s Sanofi is paying $462 million to exit the immuno-oncology pact it established with US biotech Regeneron in 2015 half a year earlier than planned.

With the severance agreement, which restructures the original deal originally scheduled to end in mid-2019, the French drugmaker will cover its share of drug discovery costs from the last quarter of 2018 as well as a termination fee and provide development support for two clinical-stage assets. 

As part of the 2015 arrangement four years ago, the Paris-based player paid Regeneron $640 million up front and committed to spending $750 million to take programs up to clinical proof of concept.

In addition increased flexibility to advance its early-stage immuno-oncology pipeline, the new arrangement gives Sanofi the right to opt in to two bispecific programs for two clinical assets as well as increased flexibility to advance its early-stage immuno-oncology pipeline.

Regeneron will retain all rights to its other immuno-oncology discovery and development programs. At the same time, it will commit up to $120 million to fund new developments in the field.

The US biotech will spend up to $70 million to develop the BCMAxCD3 drug in multiple myeloma and as much as $50 million on the MUC16xCD3 bispecific in mucin-16 expressing cancers.  If Sanofi exercises its option on the multiple myeloma asset, it will lead development and fully cover the costs. Regeneron will refund up to 50% of the costs out of its equal split of any profits.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.